Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit ...

Eli Lilly reported higher fourth-quarter profit on the back of surging demand for its GLP-1 weight-loss drugs.

The split in outlook underscores Lilly's strong position in the obesity market, underpinned by more effective drugs and its ...

CNBC's Annika Kim Constantino reports on GLP-1 demand as well as Eli Lilly and Novo Nordisk's stock performance.

After Novo Nordisk projected yesterday that its revenue could decline by as much as 13% in 2026, its share price has ...

Historical evidence indicates that abrupt market fluctuations can affect any corporation, regardless of its perceived dominance.

The rally in Lilly also pressured shares of its main weight-loss rival, Danish drugmaker Novo Nordisk ( NVO ), for a second ...

Pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) will open a $3.5 billion manufacturing facility in the Lehigh Valley community of Upper Macungie. The development will span about 925,000 square feet ...

The rivalry in the GLP-1 market between pharmaceutical leaders Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) has ...

Drugmaker Eli Lilly and Co. says it'll build a $3.5 billion manufacturing facility in Pennsylvania, as the company expands ...

The Lehigh Valley plant will be Indianapolis-based Lilly’s first manufacturing facility in Pennsylvania. Construction is ...